Latest Ratios: P/E Ratio -2.8x · EV/EBITDA N/A · ROE -89.7%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $48M | $56M | $104M | $61M | $923M | $715M | $175M | $137M | $76M | $92M | $35M |
| Enterprise Value | $36M | $43M | $93M | $66M | $859M | $606M | $175M | $143M | $84M | $89M | $33M |
| P/E Ratio → | -2.81 | — | — | — | — | 96.93 | — | — | — | — | 122.00 |
| P/S Ratio | — | — | 6.14 | 3.75 | 23.45 | 11.67 | 4.11 | 4.30 | 4.82 | 6.72 | 1.59 |
| P/B Ratio | 2.40 | 3.04 | 3.21 | 3.10 | 11.15 | 4.69 | 5.81 | 4.23 | 2.59 | 1.89 | 1.04 |
| P/FCF | — | — | — | — | — | — | — | — | — | 108.07 | — |
| P/OCF | — | — | — | — | — | — | — | — | — | 93.39 | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 5.49 | 4.04 | 21.82 | 9.90 | 4.12 | 4.48 | 5.29 | 6.48 | 1.49 |
| EV / EBITDA | — | — | — | — | — | 44.69 | — | — | — | — | 9.56 |
| EV / EBIT | — | — | — | — | — | 66.24 | — | — | — | — | 7.31 |
| EV / FCF | — | — | — | — | — | — | — | — | — | 104.21 | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 34.7% | 46.4% | 77.7% | 78.2% | 72.3% | 68.1% | 55.4% | 51.4% | 60.3% |
| Operating Margin | — | — | -218.6% | -575.5% | -211.5% | 21.2% | -34.6% | -20.2% | -131.6% | -62.2% | 13.6% |
| Net Profit Margin | — | — | -223.9% | -571.6% | -212.9% | 12.1% | -44.5% | -37.8% | -150.9% | -48.4% | 1.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -89.7% | -89.7% | -145.4% | -181.8% | -71.3% | 8.1% | -60.8% | -38.9% | -61.4% | -16.1% | 1.0% |
| ROA | -50.4% | -50.4% | -68.5% | -100.5% | -53.4% | 6.4% | -36.1% | -23.5% | -46.1% | -14.1% | 0.9% |
| ROIC | -137.9% | -137.9% | -121.1% | -327.6% | -200.8% | 26.2% | -32.1% | -12.9% | -38.2% | -16.6% | 7.5% |
| ROCE | -70.1% | -70.1% | -91.4% | -145.6% | -64.3% | 13.0% | -38.6% | -17.3% | -49.3% | -20.0% | 8.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.17 | 0.17 | 0.43 | 0.73 | 0.19 | 0.09 | 0.47 | 0.37 | 0.38 | — | — |
| Debt / EBITDA | — | — | — | — | — | 1.01 | — | — | — | — | — |
| Net Debt / Equity | — | -0.69 | -0.34 | 0.24 | -0.78 | -0.71 | 0.02 | 0.18 | 0.25 | -0.07 | -0.07 |
| Net Debt / EBITDA | — | — | — | — | — | -8.01 | — | — | — | — | -0.69 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | -3.86 | — |
| Interest Coverage | — | — | -60.03 | -37.18 | -18.18 | 1.87 | -3.34 | -1.62 | -6.82 | -4.21 | 1.36 |
Net cash position: cash ($16M) exceeds total debt ($3M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.43 | 2.43 | 2.97 | 1.29 | 2.69 | 9.62 | 1.83 | 1.20 | 0.83 | 1.88 | 5.47 |
| Quick Ratio | 2.43 | 2.43 | 2.62 | 0.91 | 2.46 | 9.27 | 1.38 | 0.94 | 0.66 | 1.37 | 4.73 |
| Cash Ratio | 2.35 | 2.35 | 2.10 | 0.54 | 2.07 | 7.76 | 0.92 | 0.45 | 0.28 | 0.60 | 0.71 |
| Asset Turnover | — | — | 0.28 | 0.33 | 0.29 | 0.34 | 0.83 | 0.59 | 0.33 | 0.25 | 0.57 |
| Inventory Turnover | — | — | 2.66 | 1.30 | 1.02 | 2.39 | 1.76 | 2.78 | 3.08 | 2.40 | 3.52 |
| Days Sales Outstanding | — | — | 85.60 | 100.93 | 32.93 | 82.19 | 44.80 | 57.63 | 91.40 | 91.38 | 177.78 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 1.0% | — | — | — | — | 0.8% |
| FCF Yield | — | — | — | — | — | — | — | — | — | 0.9% | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% |
| Shares Outstanding | — | $15M | $13M | $8M | $8M | $8M | $7M | $6M | $5M | $3M | $3M |
Imminent liquidity exhaustion risk
As indicated by the negative TTM P/E of -2.81 and the absence of forward earnings multiples, Veru's valuation is currently untethered from traditional fundamental metrics, reflecting a market pricing the equity as a deep out-of-the-money option on the success of its Enobosarm clinical development program.
The P/B ratio of 2.40 suggests that investors are assigning value to the company's intellectual property and clinical pipeline rather than its tangible asset base, which has been steadily eroding. Given the total cessation of revenue, traditional valuation multiples are largely irrelevant, and the current market capitalization appears to be driven by speculative sentiment regarding the GLP-1 adjunct market rather than historical financial performance.
Based on reported financial statements, Veru's ROIC has consistently languished in negative territory, reaching -63.2% in 2026Q2, which underscores the company's inability to generate productive returns on invested capital while it continues to fund high-cost clinical trials without a corresponding commercial revenue stream.
The persistent decay in ROIC, which plummeted to -153.1% in 2025Q2, highlights the structural challenge of maintaining a research-heavy business model without a self-sustaining commercial engine. This trend suggests that capital is being consumed at an accelerating rate relative to the value created, warranting significant caution regarding the long-term viability of the current investment strategy.
According to recent quarterly filings, the company's current ratio of 6.19 in 2026Q2 may appear superficially healthy, yet this metric is heavily distorted by the lack of operational activity and the rapid depletion of cash reserves, which have fallen to critical levels for a clinical-stage biotech.
While the quick ratio mirrors the current ratio, indicating a lack of inventory dependence, the absolute cash balance provides a very narrow runway for ongoing Phase 3 trial execution. Investors should monitor the company's ability to secure non-dilutive funding, as the current liquidity position appears insufficient to support the firm's clinical ambitions through the next fiscal year.
The current ratio is the most commonly misapplied metric for Veru, as it obscures the company's true financial distress by failing to account for the massive, non-discretionary R&D burn rate that renders standard liquidity coverage ratios largely meaningless in a pre-revenue, clinical-stage biotechnology context.
Instead of relying on the current ratio, analysts should focus on the 'cash burn rate' and 'months of runway' remaining, which provide a more accurate assessment of the company's survival timeline. Using standard liquidity ratios in this context risks providing a false sense of security that ignores the imminent need for dilutive capital raises to sustain operations.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VERU stock.
Veru Inc.'s current P/E ratio is -2.8x. The historical average is 46.6x.
Veru Inc.'s return on equity (ROE) is -89.7%. The historical average is -52.1%.
Based on historical data, Veru Inc. is trading at a P/E of -2.8x. Compare with industry peers and growth rates for a complete picture.